{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,12]],"date-time":"2026-10-12T19:55:57Z","timestamp":1791834957428,"version":"4.3.4"},"reference-count":22,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2000,5,1]],"date-time":"2000-05-01T00:00:00Z","timestamp":957139200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2000,5,1]],"date-time":"2000-05-01T00:00:00Z","timestamp":957139200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Pituitary"],"published-print":{"date-parts":[[2000,5]]},"DOI":"10.1023\/a:1009913200542","type":"journal-article","created":{"date-parts":[[2002,12,22]],"date-time":"2002-12-22T19:25:11Z","timestamp":1040585111000},"page":"277-281","source":"Crossref","is-referenced-by-count":24,"title":["Cabergoline as a First-Line Treatment in Newly Diagnosed Macroprolactinomas"],"prefix":"10.1007","volume":"2","author":[{"given":"N.","family":"Pontikides","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G.E.","family":"Krassas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E.","family":"Nikopoulou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Th.","family":"Kaltsas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"260598_CR1","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1146\/annurev.me.40.020189.001301","volume":"40","author":"ME. Molitch","year":"1989","unstructured":"Molitch ME. Management of prolactinomas. Ann Rev Med 1989;40:225\u2013232.","journal-title":"Ann Rev Med"},{"key":"260598_CR2","first-page":"2338","volume":"81","author":"BMK Biller","year":"1996","unstructured":"Biller BMK, Molitch ME, Vance ML, Cannistraro KB, Davis KR, Simons JA, Schoenfelder JR, Klibanski A. Treatment of prolactin-secreting macroadenomas with the once-weekly dopamine agonist cabergoline. J Clin Endocrinol Metab 1996;81:2338\u20132343.","journal-title":"J Clin Endocrinol Metab"},{"key":"260598_CR3","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1093\/oxfordjournals.humrep.a136464","volume":"1","author":"C Ferrari","year":"1986","unstructured":"Ferrari C, Crosignani PG. Medical treatment of hyperprolactinaemic disorders. Hum Reprod 1986;1:507\u2013514.","journal-title":"Hum Reprod"},{"key":"260598_CR4","first-page":"67","volume":"36","author":"KI Ho","year":"1988","unstructured":"Ho KI, Thorner MO. Therapeutic applications of bromocriptine in endocrine and neurological diseases. Drugs 1988;36:67\u201382.","journal-title":"Drugs"},{"key":"260598_CR5","doi-asserted-by":"crossref","first-page":"78","DOI":"10.7326\/0003-4819-100-1-78","volume":"100","author":"MC Vance","year":"1984","unstructured":"Vance MC, Evans WS, Thorner MO. Bromocriptine. Ann Intern Med 1984;100:78\u201391.","journal-title":"Ann Intern Med"},{"key":"260598_CR6","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1677\/joe.0.1190051","volume":"119","author":"JW Van't Verlaat","year":"1988","unstructured":"Van't Verlaat JW, Lancranjan I, Hendriks MJ, Croughs RJM. Primary treatment of macroprolactinomas with Parlodel LAR. Acta Endocrinol 1988;119:51\u201355.","journal-title":"Acta Endocrinol"},{"key":"260598_CR7","doi-asserted-by":"crossref","first-page":"930","DOI":"10.1016\/S0015-0282(16)53154-9","volume":"52","author":"E Ciccarelli","year":"1989","unstructured":"Ciccarelli E, Camani F, Miola C, Besser GM, Avataneo T, Grossman A. Long-term treatment with a new repeatable injectable form of bromocriptine, Parlodel LAR in patients with tumorous hyperprolactinaemia. Fertil Steril 1989;52:930\u2013935.","journal-title":"Fertil Steril"},{"key":"260598_CR8","doi-asserted-by":"crossref","first-page":"656","DOI":"10.1056\/NEJM198509123131103","volume":"313","author":"A Liuzzi","year":"1985","unstructured":"Liuzzi A, Dallabonzana D, Oppizzi G, Verde GG, Cozzi R, Chiodini P, Luccarelli G. Low doses of dopamine agonists in the long-term treatment of macroprolactinomas. N Engl J Med 1985;313:656\u2013659.","journal-title":"N Engl J Med"},{"key":"260598_CR9","doi-asserted-by":"crossref","first-page":"698","DOI":"10.1210\/jcem-60-4-698","volume":"60","author":"ME Molitch","year":"1985","unstructured":"Molitch ME, Elton RL, Blackwell RE, Caldwell B, Chang RJ, Jaffe R, Joplin G, Robbins RJ, Tyson J, Thorner MO, and the Bromocriptine Study Group. Bromocriptine as primary therapy for prolactin-secreting macroadenomas: Results of a prospective multicenter study. J Clin Endocrinol Metab 1985;60:698\u2013705.","journal-title":"J Clin Endocrinol Metab"},{"key":"260598_CR10","doi-asserted-by":"crossref","first-page":"1201","DOI":"10.1210\/jcem-68-6-1201","volume":"68g","author":"C Ferrari","year":"1989","unstructured":"Ferrari C, Mattei A, Melis GB, Paracchi A, Muratori M, Faglia G, Sghedoni D, Crosignani PG. Cabergoline: Longacting oral treatment of hyperprolactinemic disorders. J Clin Endocrinol Metab 1989;68g:1201\u20131206.","journal-title":"J Clin Endocrinol Metab"},{"key":"260598_CR11","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1111\/j.1365-2125.1987.tb03072.x","volume":"23","author":"AE Pontiroli","year":"1987","unstructured":"Pontiroli AE, Viberti GC, Mangili R, Cammelli L, Dubini A. Selective and extremely long inhibition of prolactin release in man by 1-ethyl-3 (3' dimethylamino propyl)-3-(6' allylergoline-8-b-carbonyl)-urea-diphosphate (FCE 21336). Br J Clin Pharm 1987;23:433\u2013438.","journal-title":"Br J Clin Pharm"},{"key":"260598_CR12","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1210\/jcem-66-1-193","volume":"66","author":"AM Mattei","year":"1988","unstructured":"Mattei AM, Ferrari C, Baroldi P, Cavioni V, Paracchi A. Galparoli C, Romano C, Spellecchia D, Gerevini G, Crosignani PG. Prolactin-lowering effect of acute and once weekly repetitive oral administration of cabergoline at two dose levels in hyperprolactineamic patients. J Clin Endocrinol Metab 1988;66:193\u2013198.","journal-title":"J Clin Endocrinol Metab"},{"key":"260598_CR13","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1046\/j.1365-2265.1997.1300952.x","volume":"46","author":"CI Ferrari","year":"1997","unstructured":"Ferrari CI, Abs R, Bevan JS, Brabant G, Ciccarelli E, Motta T, Mucci M, Muratori M, Musatti L, Verbessem G, Scanlon MF. Treatment of macroprolactinoma with cabergoline: A study of 85 patients. Clin Endocrinol 1997;46:409\u2013413.","journal-title":"Clin Endocrinol"},{"key":"260598_CR14","first-page":"489","volume":"126","author":"C Ferrari","year":"1992","unstructured":"Ferrari C, Paracchi A, Mattei AM, de Vincentiis S, D' Alberton A, Crosignani PG. Cabergoline in the long-term therapy of hyperprolactinemic disorders. Acta Endocrinol 1992;126:489\u2013494.","journal-title":"Acta Endocrinol"},{"key":"260598_CR15","first-page":"45","volume":"52","author":"GE Krassas","year":"1999","unstructured":"Krassas GE, Pontikides N, Kaltsas Th. Giant prolactinom presented as unilateral exophthalmos in a prepubertal boy: Response to cabergoline. Horm Res 1999;52:45\u201348.","journal-title":"Horm Res"},{"key":"260598_CR16","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1097\/00004728-199207000-00004","volume":"16","author":"P Lundin","year":"1992","unstructured":"Lundin P, Pedersen F. Volume of pituitary macroadenomas: Assessment by MRI. J Comp Ass Tom 1992;16:519\u2013528.","journal-title":"J Comp Ass Tom"},{"key":"260598_CR17","first-page":"909","volume":"904","author":"J Webster","year":"1994","unstructured":"Webster J, Piscitelli G, Polli A, Ferraci C, Ismail I, Scanlon MF, for the Cabergoline Comparative Study Group. A comparison of cabergoline and bromocriptine in the treatment of hyperprolactinemic amenorrhea. N Engl J Med 1994;331:904\u2013909.","journal-title":"N Engl J Med"},{"key":"260598_CR18","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1210\/jcem-69-4-725","volume":"69","author":"E Ciccarelli","year":"1989","unstructured":"Ciccarelli E, Giusti M, Miola C, Potenzoni F, Sghedoni D, Camanni F, Giordano G. Effectiveness and tolerability of long term treatment with cabergoline, a new long-lasting ergoline derivative, in hyperprolactinemic patients. J Clin Endocrinol Metab 1989;69:725\u2013728.","journal-title":"J Clin Endocrinol Metab"},{"key":"260598_CR19","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1016\/S0015-0282(16)60909-3","volume":"52","author":"GB Melis","year":"1989","unstructured":"Melis GB, Gambacciani M, Paoletti AM, Mais V, Sghedoni D, Fioretti P. Reduction in the size of prolactin-producing pituitary tumor after cabergoline administration. Fertil Steril 1989;52:412\u2013415.","journal-title":"Fertil Steril"},{"key":"260598_CR20","doi-asserted-by":"crossref","first-page":"3574","DOI":"10.1210\/jcem.82.11.4368","volume":"82","author":"AM Colao","year":"1997","unstructured":"Colao AM, Di Sarno A, Landi ML, Cirillo S, Sarnacchiaro F, Faciolli G, Pivonello R, Cataldi M, Merola B, Annunziato L, Lombardi G. Long term and low-dose treatment with cabergoline induces macroprolactinomas shrinkage. J Clin Endocrinol Metab 1997;82:3574\u20133579.","journal-title":"J Clin Endocrinol Metab"},{"key":"260598_CR21","first-page":"5):354","volume":"22","author":"S Cannavo","year":"1999","unstructured":"Cannavo S, Curto L, Squadrito S, Almoto B, Vieni A, Trimarchi F. Cabergoline: A ~rst-choice treatment in patients with previously untreated prolactin-secreting pituitary adenoma. J Endocrinol Invest 1999;22(5):354\u2013359.","journal-title":"J Endocrinol Invest"},{"key":"260598_CR22","doi-asserted-by":"crossref","first-page":"2518","DOI":"10.1210\/jcem.84.7.5810","volume":"84","author":"J Verhelst","year":"1999","unstructured":"Verhelst J, Abs R, Maiter D, Van Den Bruel A, Vandeweghe M, Velkeniers B, Mockel J, Lamberigts G, Petrossians P, Coremans P, Mahler C, Stevenaert A, Verlooy S, Raftopoulos C, Beckers A. Cabergoline in the treatment of hyperprolactinemia: A study in 455 patients. J Clin Endocrinol Metab 1999;84:2518\u20132522.","journal-title":"J Clin Endocrinol Metab"}],"container-title":["Pituitary"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1023\/A:1009913200542.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1023\/A:1009913200542\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1023\/A:1009913200542.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,8,4]],"date-time":"2025-08-04T04:49:53Z","timestamp":1754282993000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1023\/A:1009913200542"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2000,5]]},"references-count":22,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2000,5]]}},"alternative-id":["260598"],"URL":"https:\/\/doi.org\/10.1023\/a:1009913200542","relation":{},"ISSN":["1386-341X","1573-7403"],"issn-type":[{"value":"1386-341X","type":"print"},{"value":"1573-7403","type":"electronic"}],"subject":[],"published":{"date-parts":[[2000,5]]}}}